HTG Molecular Diagnostics (NASDAQ:HTGM) Issues Earnings Results
HTG Molecular Diagnostics (NASDAQ:HTGM) released its quarterly earnings data on Wednesday. The medical research company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.08, Fidelity Earnings reports. HTG Molecular Diagnostics had a negative return on equity of 88.60% and a negative net margin of 76.97%.
HTGM opened at $0.34 on Thursday. The firm has a market cap of $20.32 million, a P/E ratio of -0.58 and a beta of 1.33. HTG Molecular Diagnostics has a 12 month low of $0.30 and a 12 month high of $3.24. The company has a current ratio of 5.21, a quick ratio of 5.07 and a debt-to-equity ratio of 0.34. The stock has a 50-day moving average of $0.49 and a 200 day moving average of $0.67.
A number of research analysts recently weighed in on HTGM shares. ValuEngine raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of HTG Molecular Diagnostics in a research note on Tuesday, January 21st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $3.13.
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Read More: What are no-load funds?
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.